Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Gynecologic 3Gastrointestinal 3Tumor-Agnostic 2Other hematologic neoplasm 2CNS 2Breast 2Sarcoma 1Other solid neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1

Conditions

Fanconi Anemia 1

Interventions

Cyclophosphamide 94fludarabine phosphate 87Busulfan 64Cyclosporine 57Epoetin Alfa 55Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53fludarabine 45Antilymphocyte Serum 43Filgrastim 41Cytarabine 41Melphalan 40Tacrolimus 39Darbepoetin alfa 39Methotrexate 34Radiotherapy 33Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23apixaban 22Methylprednisolone 22Rivaroxaban 21Etoposide 21Thiotepa 17Dalteparin 17eltrombopag 16ferric carboxymaltose 14epoetin beta 14Daunorubicin 14Azacitidine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
prexasertib × Classical hematology × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡